Sagimet Biosciences (SGMT) Equity Ratio (2022 - 2026)
Sagimet Biosciences' Equity Ratio history spans 5 years, with the latest figure at 0.95 for Q1 2026.
- Quarterly Equity Ratio changed 0.0% to 0.95 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.95 through Mar 2026, changed 0.0% year-over-year, with the annual reading at 0.96 for FY2025, 1.65% down from the prior year.
- Equity Ratio came in at 0.95 for Q1 2026, down from 0.96 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.98 in Q1 2024 to a low of 9.23 in Q2 2023.
- The 5-year median for Equity Ratio is 0.95 (2025), against an average of 0.34.
- Year-over-year, Equity Ratio surged 116.64% in 2023 and then decreased 4.9% in 2025.
- Sagimet Biosciences' Equity Ratio stood at 5.66 in 2022, then soared by 116.64% to 0.94 in 2023, then increased by 3.26% to 0.97 in 2024, then dropped by 1.65% to 0.96 in 2025, then dropped by 0.56% to 0.95 in 2026.
- Per Business Quant, the three most recent readings for SGMT's Equity Ratio are 0.95 (Q1 2026), 0.96 (Q4 2025), and 0.93 (Q3 2025).